Search results

222 results

Sorted by Date . Sort by Relevance

Guidance Remove Guidance filter
Awaiting development Remove Awaiting development filter
In consultation Remove In consultation filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Public health guidelines Remove Public health guidelines filter
Social care guidelines Remove Social care guidelines filter
Safe staffing guidelines Remove Safe staffing guidelines filter

Sintilimab with pemetrexed and platinum-based chemotherapy for untreated advanced non-squamous non-small-cell lung cancer [ID4050]

Awaiting development [GID-TA10934] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Fordadistrogene movaparvovec for the treatment of Duchenne muscular dystrophy TS ID 10420

Awaiting development [GID-TA11044] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer TS ID 10759

Awaiting development [GID-TA11021] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma TS ID 10757

Awaiting development [GID-TA11019] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]

Awaiting development [GID-TA11033] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome or Alström syndrome ID3947

Awaiting development [GID-TA10834] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765

Awaiting development [GID-TA11050] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Bimekizumab for treating moderate to severe hidradenitis suppurativa TS ID 10637

Awaiting development [GID-TA11045] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Leniolisib for untreated activated phosphoinositide 3-kinase delta syndrome in people 12 years and over TS ID 10657

Awaiting development [GID-TA11046] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683

Awaiting development [GID-TA11053] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Selpercatinib for untreated RET-positive advanced medullary thyroid cancer in people 12 years and over TS ID 10762

Awaiting development [GID-TA11047] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy TS ID 10763

Awaiting development [GID-TA11048] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764

Awaiting development [GID-TA11049] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Cedazuridine–decitabine for untreated acute myeloid leukaemia unsuitable for intensive chemotherapy TS ID 10605

Awaiting development [GID-TA11051] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443

Awaiting development [GID-TA11052] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Empagliflozin for treating chronic kidney disease TS ID 10698

Awaiting development [GID-TA11043] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Pegvaliase for treating phenylketonuria [ID1110]

Awaiting development [GID-TA10345] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

Awaiting development [GID-TA10605] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]

Awaiting development [GID-TA10758] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

Awaiting development [GID-TA10700] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Lonafarnib for treating progeria and progeroid laminopathies [ID3867]

Awaiting development [GID-HST10039] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Awaiting development
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]

Awaiting development [GID-TA10774] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]

Awaiting development [GID-TA10776] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

Awaiting development [GID-TA10604] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

Awaiting development [GID-TA10638] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
VTS-270 for treating Niemann-Pick type C1 (ID1267)

Awaiting development [GID-HST10020] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Awaiting development
Remimazolam for general anaesthesia [ID3796]

Awaiting development [GID-TA10679] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]

Awaiting development [GID-TA10682] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

Awaiting development [GID-TA10684] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]

Awaiting development [GID-TA10685] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Gosuranemab for treating progressive supranuclear palsy [ID1607]

Awaiting development [GID-TA10553] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Durvalumab with chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]

Awaiting development [GID-TA10783] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Timrepigene emparvovec for treating choroideremia [ID3916]

Awaiting development [GID-TA10787] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]

Awaiting development [GID-TA10791] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]

Awaiting development [GID-TA10797] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

Awaiting development [GID-TA10800] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]

Awaiting development [GID-TA10811] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Trastuzumab deruxtecan for treating HER2-negative metastatic or unresectable breast cancer after chemotherapy [ID3935]

Awaiting development [GID-TA10813] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]

Awaiting development [GID-TA10823] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]

Awaiting development [GID-TA10826] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

Awaiting development [GID-TA10722] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Benralizumab for previously treated severe nasal polyps [ID1659]

Awaiting development [GID-TA10818] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]

Awaiting development [GID-TA10662] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Sotagliflozin for treating type 2 diabetes [ID1657]

Awaiting development [GID-TA10665] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]

Awaiting development [GID-TA10694] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]

Awaiting development [GID-TA10574] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]

Awaiting development [GID-TA10715] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]

Awaiting development [GID-TA10717] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]

Awaiting development [GID-TA10655] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

Awaiting development [GID-TA10336] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development